Akebia Therapeutics (AKBA) news
Recent news
Akebia Therapeutics - no significant difference in mortality: VafseO 8.77% vs ESA 8.78% per 100 patient-years
Akebia Therapeutics, Inc. (Nasdaq: AKBA) has reported findings from a post-hoc win odds analysis of its drug Vafseo® (vadadustat) in the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent patients. The analysis, based on data from the Phase 3 INNO2VATE trials, compared…
AInvest Wire · Jun 30, 2026Akebia Therapeutics - voice trial meets stopping criteria with win odds of 1.16 as of June 1, 2026
AInvest Wire · Jun 30, 2026Akebia Therapeutics Q3 EPS $(0.08), inline, sales $42.05M Miss $48.18M estimate
AInvest Wire · Nov 8, 2023ImportantAkebia Therapeutics gets FDA acceptance of resubmission of Vadadustat
Akebia Therapeutics gets FDA acceptance of resubmission of Vadadustat
AInvest Wire · Oct 25, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.